Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

LUMINATE Lighting the Way Towards in Situ Osteochondral Regeneration Through Microextrusion and Filamented Light Bioprinting

Coordinator
Universita Di Pisa, Italy
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€7.5m
Total cost
€7.5m
Partners
15 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101191804

What the project is doing

In the project's own words, from its summary on CORDIS.

Traumatic injuries to the osteochondral tissues of diarthrodial joints like the knee result in pain, functional impairment, and increased risk of developing post-traumatic osteoarthritis (PTOA) and its comorbidities. Current treatments, based on cell-free grafts or cell-based therapies, are expensive and often with limited availability, ultimately leading to total arthroplasty to relieve the pain and restore function.

However, the risk of revision of these implants is unacceptably high in young active patients, predicting a looming epidemic of revision surgeries as these implants start to fail. LUMINATE proposes a personalized, one-stage regenerative approach to target large osteochondral lesions, thus preventing PTOA and avoiding costly and invasive arthroplasty surgeries. LUMINATE will develop a next level in situ bioprinting unit, called EndoFLight, which combines three toolheads (i.e., micro-extrusion, filamented light, jetting) to print photoresins laden with patient-derived cells directly at the site of injury.

EndoFLight uses filamented light to bioprint highly architected scaffolds with excellent cell guidance properties in seconds. Together with micro-extrusion and jetting toolheads in an arthroscopic set-up, we can deposit multiple biomaterials, biomolecules and cell types together with light-assisted crosslinking of complex structures directly in vivo in a minimally invasive manner. The whole procedure will be extensively validated in a human-relevant in vivo large animal model, paving the way for clinical translation after the end of the project.

The exploitation of the results will be ensured through market analysis, the foundation of a spin-off that will commercialize the project results, and analysis of regulatory aspects of all components of the bioprinting suite. Overall, LUMINATE will ensure wide-spread health benefits to the patients suffering from these lesions and will pave the way for enormous socioeconomic advantages for our aging society.

Topics

Who is involved

OrganisationCityCountryRole
Universita Di PisaPisaItalyCoordinator
Bio InxGhentBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
European Fund Management Consulting OuTallinnEstoniaParticipant
Universitat De BarcelonaBarcelonaSpainParticipant
Optical Business & Services FiberLes UlisFranceParticipant
Faculty of Science University of ZagrebZagrebCroatiaParticipant
Sveuciliste U Zagrebu Medicinski FakultetZagrebCroatiaThird party
University of Zagreb-Faculty of Veterinary MedicineZagrebCroatiaThird party
insideAI srlBolognaItalyParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI